Results: Groups were similar regarding age, sex, hemoglobin, iron indices and total amount of IVI given monthly.

Although MDA levels at days 7 and 28, AOPP levels at days 0 and 28, CRP levels at day 28 and TNF-alpha level at day 7 were higher than at other days, there were no significant differences between the IVI groups on statistical analysis.

Conclusion: The different types and doses (intermittent or once monthly total dose) of IVI treatments are well tolerated without negative effects on the markers SB431542 of lipid and protein oxidation and inflammatory indices in chronic HD patients.”
“The aim of this study was to assess the treatment patterns of migraine and tension-type headache in the Croatian population. Analysis included the

proportion of patients who were taking specific antimigraine therapy and the number of tablets per attack per month, the proportion of patients who were taking prophylactic therapy or using alternative treatment methods and their satisfaction with the treatment. The design of the study was a cross-sectional survey. Self-completed questionnaires were randomly distributed to adults > 18 years of age in the Croatian population. A total of 616 questionnaires GSK1120212 chemical structure were analyzed: 115 patients with migraine (M), 327 patients with tension-type headache (TTH), and 174 patients with probable migraine (PM) and TTH. Specific antimigraine therapy was taken by half of patients with migraine: 35.7% of patients used triptans and 21.7% ergotamines. Prophylactic treatment had been used by 13.9% of M, 1.2% of TTH, and 6.9%

of PM patients. Alternative methods of treatment were tried by 27% of M and TTH patients. Only 16.8% of patients with M pay regular visits to physicians, while 36.3% never visited a physician. More than half of TTH patients have never visited a physician. The majority of patients are only partially satisfied with their current treatment, and almost one-third are not satisfied. Results of this study indicate that the treatment of primary headaches in Croatia should be improved.”
“Background: Reset osmostat (RO) occurs in MCC 950 36% of patients with syndrome of inappropriate antidiuretic hormone secretion (SIADH) and is not often considered when evaluating hyponatremic patients. Patients with RO are not usually treated, but recent awareness that symptoms are associated with mild hyponatremia creates a therapeutic dilemma. We encountered patients with hyponatremia, hypouricemia and high urine sodium concentration (UNa), who had normal fractional excretion (FE) of urate and excreted dilute urines that were consistent with RO. We decided to test whether a normal FEurate in nonedematous hyponatremia irrespective of UNa or serum urate would identify patients with RO.

Methods: We determined FEurate in nonedematous hyponatremic patients.